Healthcare Insider Buying: Inovio Pharmaceuticals (NYSEMKT:INO), Opko Health (NYSE:OPK), Synta Pharmaceuticals (NASDAQ:SNTA), Venaxis Inc. (NASDAQ:APPY)

Inovio Pharmaceuticals (NYSE:INO) CEO Jong Joseph Kim purchased 25,000 shares of the stock in a transaction dated Tuesday, April 15th. The stock was purchased at an average cost of $2.25 per share, for a total transaction of $56,250.00. Following the completion of the acquisition, the chief executive officer now directly owns 5,965,809 shares in the company, valued at approximately $13,423,070. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) shares after opening at $2.63 moved to $2.72 on last trade day and at the end of the day closed at $2.52. Company price to sales ratio in past twelve months was calculated as 44.83 and price to cash ratio as 11.50. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) showed a negative weekly performance of -16.00%.

Opko Health (NYSE:OPK) Chairman Jane Ph D. Hsiao bought 10,000 shares of Opko Health stock on the open market in a transaction dated Tuesday, April 15th. The stock was purchased at an average price of $8.03 per share, for a total transaction of $80,300.00. Following the transaction, the chairman now directly owns 21,338,212 shares of the company’s stock, valued at approximately $171,345,842. Opko Health Inc. (NYSE:OPK) shares fell -2.28% in last trading session and ended the day on $8.14. OPK return on equity ratio is recorded as -19.30% and its return on assets is -11.30%. Opko Health Inc. (NYSE:OPK) yearly performance is 17.12%.

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) Director Bruce Kovner bought 1,250,000 shares of Synta Pharmaceuticals Corp. stock on the open market in a transaction dated Friday, April 11th. The shares were purchased at an average price of $4.01 per share, for a total transaction of $5,012,500.00. Following the acquisition, the director now directly owns 3,048,666 shares in the company, valued at approximately $12,225,151. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) shares moved down -1.73% in last trading session and was closed at $3.97, while trading in range of $3.92 – $4.07. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) year to date (YTD) performance is -24.24%.

Venaxis Inc. (NASDAQ:APPY) SVP Donald R. Hurd purchased 35,000 shares of the stock in a transaction that occurred on Monday, April 14th. The shares were purchased at an average cost of $2.04 per share, with a total value of $71,400.00. Following the transaction, the senior vice president now directly owns 50,000 shares of the company’s stock, valued at approximately $102,000. Venaxis Inc. (NASDAQ:APPY) weekly performance is 3.24%. On last trading day company shares ended up $2.23. Venaxis Inc. (NASDAQ:APPY) distance from 50-day simple moving average (SMA50) is -12.21%. Analysts mean target price for the company is $5.67.